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TLR4Abstract Background: Colorectal carcinogenesis has been found to be associated with the poly-
morphic status of Toll-like receptor 4 gene in various populations of the world.
Aim: The aim of the study was to determine the genetic association of TLR4 gene polymor-
phisms (Asp299Gly and Thr399Ile) with disease susceptibility and risk development in colorectal
cancer (CRC) patients of Kashmir, India.
Materials and methods: Genotype frequencies of TLR4 polymorphisms (Asp299Gly and
Thr399Ile) were compared between 120 CRC patients and 200 healthy controls using PCR-
RFLP method.
Results: We did not find any significant association between the TLR4 gene polymorphisms and
the CRC cases (p> 0.05). However CT genotype (Thr399Ile) showed modest elevated risk of the
development of CRC [OR= 1.78 95% CI (0.88–3.5)]. Also G allele (AG genotype) of TLR-4
Asp299Gly polymorphism was found to be significantly associated with the male gender (p
value = 0.006) and involvement of Nodes (p value = 0.01) whereas, T allele (CT genotype) of
Thr399Ile polymorphism showed significant association with the smoking status (p value = 0.03).
Conclusion: Our results suggest that TLR4 gene polymorphism is not a key modulator of the risk
of developing colorectal cancer in Kashmiri population.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ciences,
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2 S. Nissar et al.1. Introduction
Colorectal cancer (CRC) is one of the commonly diagnosed
cancers in both men and women. It ranks third most common
cancer in men and second most in women worldwide [1]. The
incidence of this malignancy shows considerable variation
among racially or ethnically defined populations in multira-
cial/ethnic countries. Kashmir (Indian Administered) has been
reported as a high-incidence area of gastrointestinal cancers
(GIT) [1–3]. In Kashmir valley CRC represents the third most
common GIT cancer [3,4] after esophageal and gastric cancers;
and among males CRC ranks as fourth common cancer and
third among females [2,3].
Toll-like receptors (TLRs) play a vital role in immune
responses, being involved in the regulation of inflammatory
reactions and activation of the adaptive immune response to
eliminate infectious pathogens and cancer debris [5–7].
The TLR4 gene is mapped on chromosome 9 and consists
of three exons. Two common non-synonymous SNPs
(+896A/G rs4986790 and +1196C/T rs4986791) have been
found in exon 3 of gene which induce substitution of amino
acids Asp299Gly and Thr399Ile, respectively. The substitution
of Asp299Gly disrupts the normal structure of the extracellular
region of the TLR4, which may cause decreased ligand recog-
nition or protein interaction and decreased responsiveness to
lipopolysaccharide [8]. Consequently, such change can affect
the transport of TLR4 to the cell membrane and lead to an
exaggerated inflammatory response with severe tissue destruc-
tion [9].
TLR4 Asp299Gly and Thr399Ile are known to co-segregate
in 10% of the Caucasian populations and are reported to have
positive correlation with susceptibility to several diseases.
However, neither SNP is present in Asian populations [10].
CRC is one of the few cancers in which inflammation is the
basic pathological incident which later on can transform into
full blown malignancy [11–14]. Furthermore, a positive associ-
ation between various innate immune system mediators and
bacterial toxins with the development of CRC has also been
found [15]; together with the fact that TLRs serve as the medi-
ators of inflammation in the gut and are known to be crucial
regulators in maintaining the balance between commensal
bacteria in the gut and the mucosal immune system [16,17].
In addition, the potential association between TLR4 genetic
polymorphisms and the risk of bladder cancer, prostate cancer,
breast cancer, melanoma [18–21], hepatocellular carcinoma
[22], gastric cancer [23–25] and gastric mucosa associated lym-
phoid tissue lymphoma has been proposed [26]. Both TLR4
polymorphisms are also involved in advancement of Head
and neck squamous cell carcinoma (HNSCC) and may serve
as biomarkers for HNSCC [27]. In fact, some studies have
reported a significant role of TLR4 polymorphisms in increas-
ing the risk of colorectal cancer as well in their respective pop-
ulations [28,29].
Therefore, the potential role of the TLR4 polymorphisms in
the development and progression of CRC becomes much more
important to be researched upon, provided the limited data are
available on colorectal cancer.
In the present study, we conducted a case–control study to
find out the relevance of TLR4 polymorphisms (Asp299Gly
and Thr399Ile) in colorectal cancer patients of Kashmiri
population. Furthermore we also investigated whether therePlease cite this article in press as: Nissar S et al., Role of TLR4 gene polymorphisms i
control studyTLR4 gene SNP in CRC risk modulation in Kashmiri cases –>, Egypt J Mis a link between the clinic-pathological variables and the
TLR4 Asp299Gly and/or Thr399Ilegenotypes and hence their
role in modulating the risk of colorectal cancer.2. Subjects and methods
2.1. Subjects
This study included 120 consecutive primary CRC patients
recruited from Department of Surgery, Sher-I-Kashmir Insti-
tute of Medical Science, Kashmir, India. Tumor types and
stages were determined by two experienced pathologists. The
cases who had not received any chemo or radiotherapy were
chosen for this study. Blood samples of 200 age and sex
matched individuals with no signs of any malignancy were col-
lected for controls. The mean age of both patient and control
groups was 55 years.
Data on all CRC patients were obtained from personal inter-
views with patients and or guardians (for those who were illiter-
ate), medical records and pathology reports. The data collected
included sex, age, dwelling, tumor location, Dukes Stage, lymph
node status. All patients and or guardians were informed about
the study and their will to participate in this study was taken on
predesigned questionnaire (Available on request). The collec-
tion and use of tumor and blood samples for this studywere pre-
viously approved by the appropriate Institutional Ethics
Committee. The work has been carried out in accordance with
The Code of Ethics of theWorldMedical Association (Declara-
tion of Helsinki) for experiments in humans.2.2. DNA extraction & genotype analysis
DNA extraction was performed using Ammonium Acetate
Method. One lL (50 ng) of DNA was used as the template
for each PCR cycle.
Analysis of TLR-4 Asp299Gly and Thr399Ile Polymor-
phisms Genotyping was performed using PCR-RFLP method
as described previously [30]. Primers (Genescript, USA, New
Jersey) for TLR4 Asp299Gly were forward (F50 GATTAGCA
TACTTAGACTACTACCTCCATG) and reverse (R50 GAT-
CAACTTC TGA AAAAGCATTCCCAC) and Nco-I enzyme
(Fermentas, USA,Maryland) was used for digestion. Similarly,
primers for TLR4 Thr399Ile were forward (F50 GGTTGC
TGTTCTCAAAGTGATTTTGGGAGAA) and reverse (R50
CCTGAAGACTGGAGAGTGAGTTAAATGCT) and Hinf-
I (Fermentas) was used to carry out restriction digestion.
Briefly PCR was carried out in a final volume of 25 lL con-
taining 50 ng genomic DNA templaten, 1 PCR buffer with
2 mM MgCl2, 0.5 lM of each primer (Genescript), 50 lM
dNTPs (Fermentas) and 0.5 U DNA polymerase (Fermentas).
For PCR amplification, the standard program was used as fol-
lows: one initial denaturation step at 94 C for 7 min, followed
by 35 denaturation cycles of 30 sat 95 C, 30 s of annealing at
55 C, and 30 s of extension at 72 C, followed by a final
elongation cycle at 72 C for 7 min.
PCR product of 249 bp and 406 bp for TLR4 Asp299Gly
and Thr399Ile respectively were resolved for confirmation of
PCR through a 2–3 per cent agarose gel (Genie, India,
Bangalore). Both amplicons were then restriction digested at
37 C for genotypic of two SNPs.n the colorectal cancer risk modulation in ethnic Kashmiri population – A case–
ed Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.04.004
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gous wild type AA, while three bands of 249 bp, 226 bp and
23 bp were identified as heterozygous variant allele AG and
the homozygous mutant type GG displayed two bands of
226 bp and 23 bp. For, TLR4 Thr399Ile 406 bp was identified
as wild type CC, while three bands of 406 bp, 377 bp and 29 bp
were identified as heterozygous variant allele CT and the
homozygous mutant type TT displayed two bands of 377 bp
and 29 bp. The genotypes of >20 per cent of the samples were
reassessed in a double-blind manner by two independent
researchers, to confirm the results. A positive control for each
polymorphism was used for 50 per cent of the samples.
2.3. Statistical analysis
The observed frequencies of the above genotypes in patients
with CRC were compared with the controls using chi-square
or fisher exact tests when the expected frequencies were small.
The chi-square test was used to verify whether the genotype
distributions were in Hardy–Weinberg equilibrium (for allele
and genotype frequencies in our population). Statistical signif-
icance was set at p< 0.05.Statistical analyses were performed
using PASW version 18 software.
3. Results
A total of 120 cases and 200 control subjects were included in
this study with prior consent. Out of 120 confirmed cases of
CRC, 72 were males and 48 cases were females; 66 were rural
54 were urban; 52 cases had carcinoma in colon and 68 in rec-
tum; 59 were smokers and 61 non- smokers. The mean age of
patients having confirmed CRC was 55 years. Among control
subjects, 149 consisted of males and 51 females. No significant
gender- or age-related differences were observed between the
groups (p> 0.05).
Among 120 CRC cases, we found the frequency of heterozy-
gous state of TLR-4 Asp299Gly polymorphism to be 10.8%
(13/120) while the frequency in the general control population
was 15.4% (31/200). Likewise the frequency of heterozygous
state of TLR-4 Thr399Ile polymorphism was found to be
15% (18/120) in cases and 9% (18/200) among controls. Vari-
ant homozygous genotype was not found in both the polymor-
phisms in either the cases or the controls. The overall
association between the TLR4 polymorphism and the CRC
cases was found to be insignificant (p> 0.05) (Table 1).
However CT genotype showed a modest elevated risk of the
development of CRC [OR = 1.78 95%CI (0.88–3.5)]. Further-
more, analysis of the gene interactions of the two SNPs of
TLR4 gene also did not reveal any significant association
between the genotypes (p> 0.05) (Table 2).Table 1 TLR4 genotypes and allele frequencies between CRC case
SNP Controls (200) Cases (120) OR(95%C
Asp299Gly(A/G)
AA 169 (84.5%) 107 (89.1%) 1.5 (0.75–
AG 31 (15.4%) 13 (10.8%)
Thr399Ile(C/T)
CC 182 (90.9%) 102 (85.0%) 0.56 (0.27
CT 18 (9.0%) 18 (15.0%)
Please cite this article in press as: Nissar S et al., Role of TLR4 gene polymorphisms i
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polymorphism with the clinicopathological characteristics
and found the G allele carrier to be significantly associated
with the males (p value = 0.006) and involvement of lymph
nodes (p value = 0.01) (Table 3). The Thr399Ile polymor-
phism study showed the T allele carrier to be significantly asso-
ciated with the smokers (p value = 0.03) (Table 4).4. Discussion
Toll-like receptors (TLRs) belong to Type I Transmembrane
Glycoproteins, Containing three important domains: (a) the
608 residue ecto-domain – found outside the cell or in cyto-
plasm and contains multiple leucine-rich repeats (LRR) partic-
ipating in the recognition and binding of pathogens, (b) single
trans membrane domain (STM), (c) 187 residue toll/inter-
leukin 1 receptor (TIR) domain. LRRs harbor 24–29 residues
that fold into parallel b-sheets [8,10,31].
It has been found by various studies that the low-
functioning TLR4 polymorphisms usually result in reduced
inflammatory response correlating with the low-damaging
infection but a persistent infection [32–34]. Genetic variants
of TLR4 polymorphisms Asp299Gly and Thr399Ile have been
found to disrupt the structure of the extracellular region of
TLR4 protein. This in turn leads to the disturbance of normal
TLR signaling creating a pro-inflammatory environment that
favors tumor growth and chemo resistance and hence plays a
pivotal role in carcinogenesis process [35], or immunosuppres-
sion induced by chronic inflammation [7,36,37].
TLR4 Asp299Gly gene variant has an impact on TLR4 sig-
naling and potentially on intestinal homeostasis due to
impaired control signals at the epithelial cell level leading to
chronic intestinal inflammation & interrupted intestinal home-
ostasis and hence may lead to CRC [38].
In this study we evaluated the distribution of TLR4
Asp299Gly and TLR4 Thr399Ile polymorphisms in CRC
patients and controls, but we didn’t find a significant statistical
difference in the distribution among the two groups. Compar-
ing all CRC patients to healthy controls, the adjusted OR for
CRC risk was 1.5 (95% CI, 0.75–3.01) and 0.56 (95% CI,
0.27–1.12) for Asp299Gly and Thr399, respectively. We also
did not find any homozygous variant genotype among any
of the cases or controls of the study. The results are consistent
with the already published studies [10].
Although none of the two polymorphisms was found to be
significantly associated with CRC statistically, however G
allele (AG genotype) of TLR-4 Asp299Gly polymorphism
was found to be significantly associated with the male
gender (p value = 0.006) and involvement of Nodes
(p value = 0.01) (Table 3) and T allele (CT genotype) ofs and controls.
I)/Pearson p value Fisher p value (One-tailed; Two-tailed)
3.01); 0.24 0.15, 0.31
–1.12); 0.10 0.07; 0.14
n the colorectal cancer risk modulation in ethnic Kashmiri population – A case–
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Table 2 Comparative stats for the two polymorphisms for cumulative effect on CRC.
SNP Asp299Gly (A/G) OR(95%CI) Fisher p value
AA
n= 107
AG
n= 13
Thr399Ile (C/T) CC
n= 102
93 9 0.33 (0.09–1.24) 0.105
CT
n= 18
14 4
Table 3 Association of TLR4 Thr299Ile polymorphism with various clinic-pathological characteristics in CRC cases.
Characteristics N= 120 CC
102(85.0%)
CT
18(15.0%)
TT
0(0%)
OR (95%CI); p value
Age (years)
>50 62(51.6%) 51 11 0 1.57 (0.56–4.37); 0.38
650 58(48.3%) 51 7 0
Gender
Male 72(60.0%) 56 16 0 6.57(1.43–30.07); 0.006
Female 48 (40.0%) 46 2 0
Dwelling
Rural 66(55.0%) 55 11 0 1.34 (0.48–3.74); 0.57
Urban 54(45.0%) 47 7 0
Smoking status
Ever 59(49.1%) 48 11 0 1.76 (0.63–4.92); 0.27
Never 61(50.8%) 54 7 0
Tumor location
Colon 52(43.3%) 44 8 0 1.05 (0.38–2.89); 0.92
Rectum 68(56.6%) 58 10 0
Tumor grading
W.D 80(66.6%) 70 10 0 0.57 (0.20–1.58); 0.27
M.D and P.D 40(33.3%) 32 8 0
Lymph node involved
Yes 66(55%) 61 5 0 0.25(0.08–0.78); 0.019
No 54(45%) 41 13 0
W.D= well differentiated; M.D= moderately differentiated; P.D = poorly differentiated.
Significance of the association is represented in bold font of the values (p< 0.05).
4 S. Nissar et al.Thr399Ile polymorphism showed significant association with
the smoking status (p value = 0.03).
A recent meta-analysis by Sheng et al. [39] found that the
GG genotype carriers of TLR4 gene had higher risk of devel-
oping CRC than AA+ GA genotype carriers (p= 0.05). Fur-
thermore, stratified analyses showed that the genetic models of
the Asian group had higher risk of developing CRC than the
Caucasian group. They concluded that the GG genotype of
TLR4 Asp299Gly and the TT genotype of TLR4 Thr399Ile
polymorphisms might be correlated with an increased risk of
CRC, indicating that they may serve as biomarkers of disease
progression
Another meta-analysis by Li et al. [40] found an empirical
evidence of involvement of TLR4 gene in driving CRC and this
TLR4may serve as a potential biomarker for the early diagnosis
of CRC. Zhang et al., [41] in their meta-analysis for TLR4 gene
polymorphisms found both TLR4 (299/399) polymorphisms toPlease cite this article in press as: Nissar S et al., Role of TLR4 gene polymorphisms i
control studyTLR4 gene SNP in CRC risk modulation in Kashmiri cases –>, Egypt J Mbe associated with increased cancer risk and one SNP
(rs1927911) with decreased cancer risk.
Third meta-analysis by Jing et al. [7] has shown TLR4 poly-
morphisms to be positively associated with the increased risk
of digestive tract cancers. Their results suggested that
Asp299Gly has a risk effect on gastrointestinal cancers but it
tends to be a protective factor on prostate cancer. They also
reported significant geographic and ethnic differences in the
intercontinental incidence of Asp299Gly and Thr399Ile poly-
morphisms with both SNPs found to be present in 10% of
Caucasian populations. Zou et al. [42] also reported similar
results in their meta-analysis of TLR4 gene polymorphisms
and concluded that the association between TLR4 Thr399Ile
polymorphism and cancer risk was significant in both South
Asians and East Asians, but not in Caucasians.
Omrane et al. [28] found a strong association between both of
theTLR4 polymorphisms andCRC. They reported a significantn the colorectal cancer risk modulation in ethnic Kashmiri population – A case–
ed Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.04.004
Table 4 Association of TLR4 Asp299Gly polymorphism with various clinic-pathological characteristics in CRC cases.
Characteristics N= 120 AA
107 (89.1%)
AG
13 (10.8%)
GG
0(0%)
OR (95%CI); p value
Age (years)
650 62(51.6%) 54 8 0 1.57 (0.48–5.11); 0.45
>50 58(48.3%) 53 5 0
Gender
Male 72(60.0%) 63 9 0 1.57 (0.45–.5.42); 0.47
Female 48(40.0%) 44 4 0
Dwelling
Rural 66(55.0%) 62 4 0 0.32 (0.09–1.11); 0.06
Urban 54(45.0%) 45 9 0
Tumor location
Colon 52(43.3%) 48 4 0 0.54 (0.15–1.88); 0.33
Rectum 68(56.6%) 59 9 0
Smoking status
Ever 59(49.1%) 49 10 0 3.94(1.02–15.14); 0.03
Never 61(50.8%) 58 3 0
Tumor grading
W.D 80(66.6%) 71 9 0 1.14 (0.32–3.95)
M.D and P.D 40(33.3%) 36 4 0
Lymph node involved
Yes 66(55.0%) 57 9 0 1.97 (0.57–6.80); 0.27
No 54(45.0%) 50 4 0
W.D= well differentiated; M.D= moderately differentiated; P.D = poorly differentiated.
Significance of the association is represented in bold font of the values (p< 0.05).
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pathological parameters (tumor differentiation (p = 0.027)
and tumor architecture (p = 0.02), advanced stage (p = 0.03)
and concluded that TLR4 polymorphisms may serve as poten-
tial biomarker of CRC progression.
Pimentel-Nunes et al. [29] in their study on European CRC
patients reported that the functional polymorphisms in TLR2
and TLR4 significantly alter the risk of developing CRC. Fur-
thermore they also reported that the risk of cancer gets exem-
plified in the overweight individuals.
However, there are a number of studies on various popula-
tions which have observed a non-association of TLR4 gene
polymorphisms with the risk of modulating CRC [43,44]. A
number of studies have shown overexpression of TLR4 to be
associated with the metastatic colorectal cancer [45–47]; while
as a few have shown that loss of expression or strong downreg-
ulation of TLR4 is associated with the metastatic colorectal
cancer [48], while some reported no change in expression by
variant status of TLR4 [11].
Furthermore, a number of studies reported from India on
various cancers have implicated TLR4 polymorphism in mod-
ulating the risk of cancers [49–52]. So, our study is also an
extension of such efforts to elucidate the role played by various
genetic polymorphisms in modulating the risk of CRC.
5. Conclusion
In conclusion, our results suggest that TLR4 gene polymor-
phism is not a key modulator of the risk of developing colorec-
tal cancer in Kashmiri population.Please cite this article in press as: Nissar S et al., Role of TLR4 gene polymorphisms i
control studyTLR4 gene SNP in CRC risk modulation in Kashmiri cases –>, Egypt J MConflict of interest
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